LivaNova (LIA) AI Stock Analysis

Company Guidance

For full year 2026, LivaNova now expects cardiopulmonary revenue to grow 10.5% to 11.5%, epilepsy revenue growth of 8% to 9%, and total revenue growth between 9% to 10% on a constant currency basis, with foreign currency a tailwind of approximately 1%; HLM unit placements are expected to be 80% of annual placements, adjusted operating income margin is expected to be in the range of 20% to 21%, adjusted effective tax rate approximately 23%, adjusted diluted earnings per share $4.40 to $4.50, adjusted diluted weighted average shares outstanding approximately 56 million, and adjusted free cash flow in the range of $140 million to $160 million, including $135 million in capital spending, while the net impact from tariffs is expected to be less than $5 million on full year adjusted operating income; the company expects double digit capacity expansion in 2027, a limited OSA launch in 2027, the next-generation IPG and digital health platform market release in 2027, material revenue impact from the heater cooler and Air Manager beyond 2027, starting 2028, and new category 1 codes subject to finalization expected to take effect on January 1, 2028.